These results conformed closely to those reported in pancreatic cancer [15], esophageal cancer [14] and breast cancer [13], further providing evidence that IRF-2 overexpression might be associated with tumorigenesis of CRC. This evidence concerns the gene IRF2 and pancreatic neoplasm.